Multiple studies presented at 2014 ASCO annual meeting reinforce unique, practice-changing value of Oncotype DXÂ® breast cancer test
Demonstrate importance of consistent results from multiple validation studies
Highlight substantial differences between multi-gene tests
Reinforce Genomic Healthâ#$%$™s commitment to improving the quality of treatment decisions for cancer patients
GENEVA, Switzerland--(BUSINESS WIRE)-- Genomic Health, Inc.Â (Nasdaq: GHDX) announced results of three studies with the Oncotype DX breast cancer test at the recent 2014 American Society of Clinical OncologyÂ® (ASCOÂ®) Annual Meeting.